<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349439</url>
  </required_header>
  <id_info>
    <org_study_id>08-44</org_study_id>
    <nct_id>NCT01349439</nct_id>
  </id_info>
  <brief_title>Reducing Reconsolidation of Trauma Memories With Propranolol</brief_title>
  <official_title>Reduction of the Reconsolidation of the Trauma Memory With Propranolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Douglas Mental Health University Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Douglas Mental Health University Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether propranolol is capable of reducing subsequent
      physiological trauma-related conditioned responses, as well as self-reported post-traumatic
      stress disorder (PTSD) symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electromyogram</measure>
    <time_frame>Two weeks post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Two weeks post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin conductance</measure>
    <time_frame>Two weeks post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD symptom levels</measure>
    <time_frame>2 to 26 weeks</time_frame>
    <description>PTSD symptom levels will be assessed 2 to 26 weeks after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 to 26 weeks</time_frame>
    <description>Quality of life assessments will be conducted 2 to 26 weeks following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory Experience</measure>
    <time_frame>2 to 26 weeks</time_frame>
    <description>The Memory Experiences Questionnaire will be administered from 2 to 26 weeks following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychophysiological assessments</measure>
    <time_frame>26 weeks</time_frame>
    <description>Psychophysiological assessments will be repeated 26 weeks following randomization</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Propranolol + Memory Reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm involves recalling the traumatic event after administration of propranolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Memory reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm involves recalling the traumatic event after administration of a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + No Memory Reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm involves administration of a placebo without recalling the traumatic event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol + No Memory Reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm involves administration of propranolol without recalling the traumatic event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Propranolol + Memory Reactivation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>1mg per Kg (participant weight)</description>
    <arm_group_label>Propranolol + Memory Reactivation</arm_group_label>
    <arm_group_label>Placebo + Memory reactivation</arm_group_label>
    <arm_group_label>Placebo + No Memory Reactivation</arm_group_label>
    <arm_group_label>Propranolol + No Memory Reactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short acting + long acting propranolol + memory reactivation</intervention_name>
    <description>After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.</description>
    <arm_group_label>Open-label Propranolol + Memory Reactivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffer from chronic PTSD for at least 6 consecutive months;

          -  Obtain a score of 33 or more on the Impact of Events Scale-Revised:

          -  For participants aged 40 years: accept to undergo an electrocardiogram assessment. The
             results of the electrocardiogram must be normal;

          -  Accept to not commence taking new medications on a regular basis during the study.

        Exclusion Criteria:

          -  Hypotension;

          -  Cardiac rhythm below 55 beats per minute;

          -  Medical conditions that contraindicates the administration of propranolol;

          -  Previous adverse reaction to, or non-compliance with, beta-blockers;

          -  Current use of medication that may involve potentially dangerous interactions with
             propranolol;

          -  Any medication that can have an impact on cardiac rhythm;

          -  Women who are breast feeding;

          -  Past or present bipolar disorder or psychosis,

          -  Present substance abuse or dependence, suicidal ideation;

          -  Participating in psychotherapy other than support psychotherapy;

          -  An average score above 20 on the Dissociative Experience Scale.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Brunet, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Douglas Institute Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain R Brunet, Ph.D.</last_name>
    <phone>514-761-6131</phone>
    <phone_ext>4348</phone_ext>
    <email>alain.brunet@mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Douglas Mental Health University Institute</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ashbaugh, Ph.D.</last_name>
      <phone>514-761-6131</phone>
      <phone_ext>4341</phone_ext>
      <email>andrea.ashbaugh@douglas.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Alain Brunet, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22.</citation>
    <PMID>17588604</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Douglas Mental Health University Institute</investigator_affiliation>
    <investigator_full_name>Alain Brunet, Ph.D.</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

